c19early.org/f
c19hcq.org
c19early.org
Fluvoxamine for COVID-19:
https://c19early.org/f
https://c19hcq.org
https://c19early.org
* 17 studies from 414 scientists
* 36,705 patients in 8 countries
* Statistically significant improvement for mortality, hospitalization, and cases.
11 studies from 11 independent teams in 6 countries show statistically significant improvements in isolation.
HCQ for COVID-19
* 389 studies from 8,250 scientists
* 513,900 patients in 57 countries
* Statistically significant improvement for mortality, hospitalization, recovery, cases, and viral clearance.
* 62%, 19% improvement for early and late treatment CI [52-70%], [15-23%]; 36, 252 studies
* 23% improvement in 8 early treatment RCTs CI [-20-51%]
* 72% less death in 15 early treatment trials CI [57-81%]
Brilliant. Thank you so much!
undefined subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.
https://c19early.org/f
https://c19hcq.org
https://c19early.org
Fluvoxamine for COVID-19:
* 17 studies from 414 scientists
* 36,705 patients in 8 countries
* Statistically significant improvement for mortality, hospitalization, and cases.
11 studies from 11 independent teams in 6 countries show statistically significant improvements in isolation.
HCQ for COVID-19
* 389 studies from 8,250 scientists
* 513,900 patients in 57 countries
* Statistically significant improvement for mortality, hospitalization, recovery, cases, and viral clearance.
* 62%, 19% improvement for early and late treatment CI [52-70%], [15-23%]; 36, 252 studies
* 23% improvement in 8 early treatment RCTs CI [-20-51%]
* 72% less death in 15 early treatment trials CI [57-81%]
Brilliant. Thank you so much!